Claims
- 1. A pharmaceutical composition as an anti-cancer agent against carcinoma, comprising a synergistic combination, not merely additive effect, of the following active ingredients:
- (i) a therapeutically effective amount, for the treatment of carcinoma, of L-ascorbic acid or a pharmaceutically acceptable salt thereof; and
- (ii) a therapeutically effective amount, for the treatment of carcinoma, of a compound selected from the group consisting of 5,6-O-benzylidene-L-ascorbic acid and pharmaceutically acceptable salts of said acid.
- 2. A pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable salts are selected from the group consisting of alkali metal salts and alkaline earth metal salts.
- 3. A pharmaceutical composition according to claim 1 of 2, further comprising a pharmaceutically acceptable carrier or excipient for oral administration.
- 4. A pharmaceutical composition according to claim 3, comprising from 0.1 to 20% by weight of said active ingredient (ii) and an equivalent amount of said active ingredient (i).
- 5. A pharmaceutical composition according to claim 1 or 2, further comprising a pharmaceutically acceptable carrier or excipient for parenteral administration.
- 6. A pharmaceutical composition according to claim 5, comprising from 0.1 to 10% by weight of each of said active ingredients (i) and (ii).
- 7. A method for the treatment of carcinoma in a patient, which comprises administering to said patient a synergistic combination, not merely additive effect, of:
- (i) a therapeutically effective amount, for the treatment of carcinoma, of L-ascorbic acid or a pharmaceutically acceptable salt thereof; and
- (ii) a therapeutically effective amount, for the treatment of carcinoma, of a compound selected from the group consisting of 5,6-O-benzylidene-L-ascorbic acid and pharmaceutically acceptable salts of said acid.
- 8. A method according to claim 7, wherein said active ingredients (i) and (ii) are administered simultaneously by the administration of a composition comprising said active ingredients (i) and (ii).
- 9. A method according to claim 7, wherein said active ingredients (i) and (ii) are separately administered.
- 10. A method according to any one of claims 7-9, wherein from 1.5-3 g of the said active ingredient (ii) are administered orally to an adult patient per day in conjunction with up to 5 g of said active ingredient (i).
- 11. A method according to any one of claims 7-9, wherein from 1.5-3 g of said active ingredient (ii) are administered by infusion to an adult patient per day in conjunction with from 5-10 g of said active ingredient (i).
Parent Case Info
This application is a division of U.S. Ser. No. 07/275,091 filed Nov. 21, 1988, now U.S. Pat. No. 5,032,610.
Foreign Referenced Citations (1)
Number |
Date |
Country |
0148094 |
Jul 1985 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Cameron et al., Cancer Research 39, pp. 663-681, Mar. 1979. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
275091 |
Nov 1988 |
|